Additionally, RJ has been shown to activate AMPK in animal models, reducing hepatic gluconeogenesis and ameliorating non-alcoholic fatty liver disease by enhancing insulin sensitivity, suppressing hepatic lipogenesis, and stimulating fatty acid oxidation via AMPK-dependent pathways [50,51]. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatotic liver disease.